Back استرات ايثيل حمض أوميجا 3 Arabic ଓମେଗା-3 ଏସିଡ ଇଥାଇଲ ଇଷ୍ଟର ସମୂହ OR Омакор Russian Este ethyl acid omega-3 Vietnamese
 Chemical structure of ethyl eicosapentaenoate, an important omega-3-acid ethyl ester | |
| Combination of | |
|---|---|
| Eicosapentaenoic acid | Antilipemic agent |
| Docosahexaenoic acid | Antilipemic agent |
| Clinical data | |
| Trade names | Lovaza, Omtryg, others |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Omega-3-acid ethyl esters are a mixture of ethyl eicosapentaenoic acid and ethyl docosahexaenoic acid, which are ethyl esters of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil.[3] Together with dietary changes, they are used to treat high blood triglycerides which may reduce the risk of pancreatitis.[3][4] They are generally less preferred than statins, and use is not recommended by NHS Scotland as the evidence does not support a decreased risk of heart disease.[3][5][6] Omega-3-acid ethyl esters are taken by mouth.[3]
Common side effects include burping, nausea, and an upset abdomen.[3][5] Serious side effects may include liver problems and anaphylaxis.[3] While use in pregnancy has not been well studied, some omega-3 fatty acids appear beneficial.[1] How it works is not entirely clear.[3]
Experts found a dose-dependent increase in the risk for atrial fibrillation in patients with cardiovascular diseases or cardiovascular risk factors who were being treated with omega-3-acid ethyl esters compared with those treated with placebo. The observed risk was at its highest at a dose of 4 g/d.[1]
Omega-3-acid ethyl ester medicines were approved for medical use in the European Union in 2000 and in the United States in 2004.[3][6][7] Beyond the branded prescription formulation, it is also available as a generic medication and over the counter.[3][5] In 2021, it was the 218th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[8][9]
- ^ a b "Omega-3 polyunsaturated fatty acids Use During Pregnancy". Drugs.com. Retrieved 13 April 2019.
- ^ Cite error: The named reference
emcwas invoked but never defined (see the help page). - ^ a b c d e f g h i "Omega-3-acid Ethyl Esters Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 13 April 2019.
- ^ Karalis DG (February 2017). "A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids". Advances in Therapy. 34 (2): 300–323. doi:10.1007/s12325-016-0462-y. PMC 5331085. PMID 27981496.
- ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 206–207. ISBN 9780857113382.
- ^ a b "Omega-3 fatty acid medicines". European Medicines Agency. 17 September 2018. Retrieved 13 April 2019.
- ^ "Drug Approval Package: Omacor (Omega-3-Acid Ethyl Esters) NDA #021654". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 15 May 2020.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Omega-3-acid Ethyl Esters - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search